46 related articles for article (PubMed ID: 29479063)
21. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
22. PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity.
Szydłowski M; Dębek S; Prochorec-Sobieszek M; Szołkowska M; Tomirotti AM; Juszczyński P; Szumera-Ciećkiewicz A
Am J Pathol; 2021 Mar; 191(3):567-574. PubMed ID: 33307035
[TBL] [Abstract][Full Text] [Related]
23. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
24. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
25. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
26. High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
La Starza R; Messina M; Gianfelici V; Pierini V; Matteucci C; Pierini T; Limongi MZ; Vitale A; Roti G; Chiaretti S; Foà R; Mecucci C
Leukemia; 2018 Aug; 32(8):1807-1810. PubMed ID: 29479063
[No Abstract] [Full Text] [Related]
27. T-cell lymphoblastic leukemia/lymphoma with t(7;14)(p15;q32) [TCRγ-TCL1A translocation]: a case report and a review of the literature.
Sugimoto KJ; Shimada A; Wakabayashi M; Sekiguchi Y; Izumi H; Ota Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(5):2615-23. PubMed ID: 24966976
[TBL] [Abstract][Full Text] [Related]
28. Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M; Nicot C
Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
[TBL] [Abstract][Full Text] [Related]
29. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
30. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
31. Why target PIM1 for cancer diagnosis and treatment?
Magnuson NS; Wang Z; Ding G; Reeves R
Future Oncol; 2010 Sep; 6(9):1461-78. PubMed ID: 20919829
[TBL] [Abstract][Full Text] [Related]
32. T-cell acute lymphoblastic leukemia associated with complex karyotype and SET-NUP214 rearrangement: a case study and review of the literature.
Lee SG; Park TS; Cho SY; Lim G; Park GJ; Oh SH; Cho EH; Chong SY; Huh JY
Ann Clin Lab Sci; 2011; 41(3):267-72. PubMed ID: 22075511
[TBL] [Abstract][Full Text] [Related]
33. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
34. Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
Wenzinger C; Williams E; Gru AA
Curr Hematol Malig Rep; 2018 Aug; 13(4):275-288. PubMed ID: 29951888
[TBL] [Abstract][Full Text] [Related]
35. PAX5-AUTS2 fusion resulting from t(7;9)(q11.2;p13.2) can now be classified as recurrent in B cell acute lymphoblastic leukemia.
Coyaud E; Struski S; Dastugue N; Brousset P; Broccardo C; Bradtke J
Leuk Res; 2010 Dec; 34(12):e323-5. PubMed ID: 20723977
[No Abstract] [Full Text] [Related]
36. ETP-ALL with aberrant B marker expression: Case series and a brief review of literature.
Garg S; Gupta SK; Bakhshi S; Mallick S; Kumar L
Int J Lab Hematol; 2019 Apr; 41(2):e32-e37. PubMed ID: 30407727
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
